SYSTEMIC SCLERODERMA TREATMENT MARKET ANALYSIS

Systemic Scleroderma Treatment Market, by Drug Class (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, and Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)), by Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4641
Pages :164
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Systemic Scleroderma Treatment Market - Restraint

The lack of a standard framework for evaluating systemic scleroderma therapeutics and clinical trial failure are the factors that are expected to hinder growth of the global systemic scleroderma treatment market over the forecast period. For instance, in September 2020, Lenabasum, an oral cannabinoid-2 agonist manufactured by Corbus Pharmaceuticals Holdings Inc., a U.S. based clinical stage pharmaceutical company failed to show positive phase III efficacy in treatment of diffuse cutaneous systemic sclerosis despite showing benefits in phase II clinical trial results.

Restraints & Challenges:

Lack of a standard framework for evaluating systemic scleroderma therapeutics
Failure of clinical trials associated with development of systemic scleroderma therapeutics

Growth Drivers: